US Stock MarketDetailed Quotes

TAK Takeda Pharmaceutical

Watchlist
  • 13.110
  • -0.250-1.87%
Close Dec 18 16:00 ET
41.71BMarket Cap22.30P/E (TTM)

Takeda Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Takeda Pharmaceutical Q2 2025 Earnings Date

Currency：JPYOct 31, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
1.08T
1.18T
+96.82B
Beat Est.
+3.46%
+12.75%
+8.97%
EPS
--
28.59
--
+286.34%
Analyst Rating
Buy

Nov 30, 2024

Takeda Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 1.042T--
Jan 30, 20252025/Q3-- / 1.132T--
Oct 31, 20242025/Q21.176T / 1.079T--
Jul 31, 20242025/Q11.208T / 1.081T--
May 9, 20242024/Q41.051T / 899.902B--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q4-- / 1.042T--
Jan 30, 20252025/Q3-- / 1.132T--
Oct 31, 20242025/Q21.176T / 1.079T--
Jul 31, 20242025/Q11.208T / 1.081T--
May 9, 20242024/Q41.051T / 899.902B--

Unlock Free Earnings Estimates

Takeda Pharmaceutical Earnings Reports

  • 6-K: Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

    Dec 13 06:16 ET

  • 6-K: Semi-annual Securities Report

    Oct 31 06:31 ET

  • 6-K: Earnings Report for the Six-month Period Ended September 30, 2024

    Oct 31 06:26 ET

  • 6-K: Notice of the Revised Forecast of Consolidated Financials for FY2024

    Oct 31 06:21 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 30, 2024

    Buy

    • Buy

      50.00%

    • Hold

      50.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data

    Investment Theme Infectious Disease
    Infectious Disease
    Intraday-2.21%